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Antimicrobial Prescribing in Dogs and Cats in Australia: Results of
the Australasian Infectious Disease Advisory Panel Survey
L.Y. Hardefeldt , S. Holloway, D.J. Trott, M. Shipstone, V.R. Barrs, R. Malik, M. Burrows,
S. Armstrong, G.F. Browning, and M. Stevenson
Background: Investigations of antimicrobial use in companion animals are limited. With the growing recognition of the
need for improved antimicrobial stewardship, there is urgent need for more detailed understanding of the patterns of antimi-
crobial use in this sector.
Objectives: To investigate antimicrobial use for medical and surgical conditions in dogs and cats by Australian
veterinarians.
Methods: A cross-sectional study was performed over 4 months in 2011. Respondents were asked about their choices of
antimicrobials for empirical therapy of diseases in dogs and cats, duration of therapy, and selection based on culture and sus-
ceptibility testing, for common conditions framed as case scenarios: 11 medical, 2 surgical, and 8 dermatological.
Results: A total of 892 of the 1,029 members of the Australian veterinary profession that completed the survey satisﬁed
the selection criteria. Empirical antimicrobial therapy was more common for acute conditions (76%) than chronic conditions
(24%). Overall, the most common antimicrobial classes were potentiated aminopenicillins (36%), ﬂuoroquinolones (15%),
ﬁrst- and second-generation cephalosporins (14%), and tetracyclines (11%). Third-generation cephalosporins were more fre-
quently used in cats (16%) compared to dogs (2%). Agreement with Australasian Infectious Disease Advisory
Panel (AIDAP) guidelines (generated subsequently) was variable ranging from 0 to 69% between conditions.
Conclusions and Clinical Importance: Choice of antimicrobials by Australian veterinary practitioners was generally appro-
priate, with relatively low use of drugs of high importance, except for the empirical use of ﬂuoroquinolones in dogs, particu-
larly for otitis externa and 3rd-generation cephalosporins in cats. Future surveys will determine whether introduction of the
2013 AIDAP therapeutic guidelines has inﬂuenced prescribing habits.
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Antimicrobial resistance develops in response toantimicrobial use1–3 regardless of the animal species
being treated, with greater use likely to contribute to
development of resistance to multiple drug classes. This is
a growing threat in human hospitals, the community and
in companion and production animals. Veterinary
antimicrobial usage, has come under increasing scrutiny
by medical, public health, and government oﬃcials,
especially in food-producing animals. In companion ani-
mals, an apparent increase, or increased reporting of mul-
tidrug-resistant pathogens, especially coagulase-positive
staphylococcal species,4–7 suggests that investigation of
patterns of antimicrobial usage in companion animal
practice is needed. Since the registration of ﬂuoro-
quinolones (ie, enroﬂoxacin, marboﬂoxacin, diﬂoxacin,
orbiﬂoxacin, and most recently pradoﬂoxacin) starting in
1989 and an injectable long-acting 3rd-generation cepha-
losporin (cefovecin) in 2008, for speciﬁc use in dogs and
cats, antimicrobial usage patterns in Australian compan-
ion animal practice have not been examined.
Data on antimicrobial use in companion animal prac-
tice in Australia are limited to a single cross-sectional
study carried out in 1997.8 In this survey, respondents
were asked about patterns of use of various systemic
antibacterial drugs and their approach to treatment of 9
speciﬁc medical scenarios. Penicillins and cephalospor-
ins were the most commonly used drugs, with amoxi-
cillin-clavulanate the most frequently prescribed
antimicrobial agent. Empiric antibiotic therapy was
used in the vast majority of acute medical conditions
(76–94% of cases) and was frequently used in chronic
conditions (15–50% of cases).
From the Faculty of Veterinary and Agricultural Sciences, Asia-
Paciﬁc Centre for Animal Health, University of Melbourne,
Melbourne, (Hardefeldt, Browning, Stevenson); Advanced Vetcare,
Kensington, Vic. (Holloway); School of Animal and Veterinary
Sciences, University of Adelaide, Adelaide, SA (Trott); School of
Veterinary Sciences, University of Queensland, Gatton, Qld
(Shipstone); Faculty of Veterinary Science, University of Sydney,
Sydney, NSW (Barrs, Malik); Animal Dermatology, Perth, WA
(Burrows); and the Zoetis Animal Health, Rhodes, NSW Australia
(Armstrong).
The survey was designed by the AIDAP panel and undertaken by
Pﬁzer Animal Health Australia in 2011 (now Zoetis Animal Health
Australia). Analysis of the survey data was performed at the Univer-
sity of Melbourne.
The article has not been presented at any meetings.
Corresponding author: L. Hardefeldt, Melbourne Veterinary
School, University of Melbourne, Parkville, Vic. 3052, Australia;
e-mail: laura.hardefeldt@unimelb.edu.au.
Submitted December 11, 2016; Revised March 15, 2017;
Accepted April 11, 2017.
Copyright © 2017 The Authors. Journal of Veterinary Internal
Medicine published by Wiley Periodicals, Inc. on behalf of the Ameri-
can College of Veterinary Internal Medicine.
This is an open access article under the terms of the Creative
Commons Attribution-NonCommercial License, which permits use,
distribution and reproduction in any medium, provided the original
work is properly cited and is not used for commercial purposes.
DOI: 10.1111/jvim.14733
Abbreviations:
AIDAP Australasian Infectious Disease Advisory Panel
C & S culture and sensitivity
IQR interquartile range
IRSAD index for relative socioeconomic advantage-
disadvantage
LUTI lower urinary tract infection
Standard Article
J Vet Intern Med 2017;31:1100–1107
The Australian Strategic and Technical Advisory
Group on Antimicrobial Resistance have issued an
importance rating and summary of antibacterials used
in human health in Australia in 2015. Those given a
high importance rating include piperacillin-tazobactam,
ticarcillin-clavulanate (now no longer manufactured but
available at the time of the survey), the 3rd- and 4th-
generation cephalosporins, aztreonam, tigecycline, van-
comycin, teicoplanin, amikacin, the streptogramins (eg,
pristinamycin), ﬂuoroquinolones, and rifampicin.9 These
antimicrobials should be treated as third-line therapies
and should only be used where culture and susceptibil-
ity (C & S) testing or other compelling clinical evidence
indicates their use. Of the antimicrobials with a high
importance rating, only the 3rd-generation cephalospor-
ins and ﬂuoroquinolones are registered for use in dogs
and cats in Australia.
The Australasian Infectious Disease Advisory
Panel (AIDAP) was convened with a view to developing
antimicrobial and therapeutic guidelines for common
medical, surgical and dermatological conditions seen in
general veterinary practice in Australia. These guidelines
were released in 2013 and include evidence-based rec-
ommendations, where possible, and specialist veterinary
opinion where there was a limited evidence base.
The aims of this study were to investigate empirical
antimicrobial use (ie, drug choices), the frequency of
use of C & S testing as a tool for selecting antimicro-
bials, and the proportion of “high importance” rating
antimicrobials, through case scenario presentations to
identify likely practitioner prescribing behavior. A sec-
ondary aim was to determine the frequency of agree-
ment of antimicrobial use with the AIDAP therapeutic
guidelines which were generated after the survey had
been conducted.
Methods
The source population for the survey was clinicians
practicing veterinary medicine in Australia in 2011. At
that time, there were an estimated 7,300 registered vet-
erinarians in Australia. To be 95% certain that this esti-
mate of the prevalence of veterinarians using a given
class of antimicrobial was within 5% of a true preva-
lence of 50%, a total of 365 completed surveys were
required. Sample size calculations were carried out
assuming a 50% prevalence because this provided the
largest sample size estimate for a constant margin of
error. Respondents were self-selected and were encour-
aged to participate through a variety of electronic and
print media sources over a 4-month period in 2011.
The survey was created online by web-based designers
in coordination with the AIDAP (questionnaire avail-
able as Supporting Information). There were 3 sections.
The ﬁrst section asked for the respondent’s veterinary
board registration number, year of graduation, and an
estimate of the proportion of clinical work they per-
formed on cats, dogs, horses, production animal, or
other species. In the second section, respondents were
asked to indicate their usual (>50% of the time)
approach to the treatment of cats and dogs for each of
11 speciﬁc medical disorders when clinical evidence sug-
gested the presumptive diagnosis. They were also asked
about their approaches to 2 surgical conditions; routine
desexing and dental scaling and polishing, with tooth
extractions. The speciﬁed disorders included abscess/cel-
lulitis, chronic gingivostomatitis/“faucitis,” acute febrile
illness, peritonitis, chronic rhinosinusitis, pyothorax,
acute upper and lower respiratory tract infections, acute
and recurrent lower urinary tract infections (LUTI)/cys-
titis and LUTI with concurrent chronic kidney disease.
The third section asked about management of selected
dermatological conditions and otitis externa, including
surface, superﬁcial and deep pyodermas, dermatophyto-
sis, and superﬁcial yeast infections of the skin, as well
as uncomplicated and refractory otitis externa. Both
open and closed questions were used. Drop-down
menus provided lists of commercially available antimi-
crobials from which respondents could select their
favored therapy.
Data were downloaded from the Website to spread-
sheets (Microsoft Oﬃce Access, Microsoft Oﬃce Excel).
Any questions not completed by a respondent were
excluded from the analysis of that question. Simple
descriptive statistics were computed with percentages
being reported as a proportion of the total number of
respondents answering a particular question. Given that
this study did not use a simple random sampling design,
data were analyzed to account for overrepresentation
by state of practice.10 Sampling weights provided an
estimate of the inverse probability of a veterinarian’s




where Ni is the number of registered veterinarians in
the state in 2011, and n is the number of veterinarians
from that state who completed the survey. Throughout
this article, all profession level data are described using
adjusted values based on survey design, sampling
weights, and ﬁnite correction factors. Proportions of
questionnaire responses are reported as unadjusted
counts.
The index for relative socioeconomic advantage-dis-
advantage (IRSAD) and usual resident population of
each postcode for participants in the survey was
accessed from the Australian Bureau of Statistics.11
Regression models were used to quantify the associa-
tion between individual respondent-level variables (year
of graduation, percentage of small versus large animal
practice, IRSAD) and the probability of a veterinarian
prescribing in such a way that agreed with the AIDAP
guidelines. For continuously distributed explanatory
variables, a Shapiro-Wilk test for normality was used.
Diﬀerences in independent medians were assessed using
the Mann-Whitney tests. A binary logistic regression
model was developed with year of graduation expressed
as a 2-level categorical variable: <5 years since gradua-
tion and 5 or greater years since graduation. The
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proportion of time spent on small animal practice was
expressed as a 2-level categorical variable: those that
spent more than 70% of their time working with com-
panion animals (“companion animal practitioners”) and
those that spent 70% or less of their time working
with companion animals (“mixed animal practitioners”).
The binary outcome variable for this analysis was
whether or not the reported antimicrobial usage pat-
terns reported by the respondent were consistent with
AIDAP guidelines or not. Descriptive analysis and the
logistic regression analysis were carried out using Stata
version 13a .
This study was organized and sponsored by a veteri-
nary pharmaceutical company, and ethics clearance was
not required by the University of Melbourne as no
identifying information was used in the analysis.
Results
A total of 1,029 Australian veterinary practitioners
completed the survey. Of these, 892 satisﬁed the selec-
tion criteria for inclusion, representing more than 12%
of the total number of registered veterinarians in 2011.
All states and territories were represented, as were
recent and older graduates. More than 70% of respon-
dents were companion animal practitioners. Only 4.5%
of respondents had a caseload in which <50% of
patients were dogs and cats.
As there was no diﬀerence in the frequency with
which empirical antimicrobial therapy was used rather
than antimicrobial therapy directed by the results of C
& S testing between dogs and cats, the results were
combined for each question. Overall, antimicrobial
selections were empirical in 51% (7,290 of 14,414) of
cases (range 8–79%), guided by C & S in 26% (3,694 of
14,414) of cases (range 0.1–70%), and empirical therapy
was employed pending the results of C & S testing in
24% (3,430 of 14,414) (range 13–32%) of cases. There
were 3 conditions in which C & S testing was used by
>80% of respondents: pyothorax (80%, 95% CI 78–
83%), recurrent LUTI (92%, 95% CI 91–94%) and
LUTI with chronic kidney disease (80%, 95% CI 78–
82%). Antimicrobial therapy guided by C & S was also
commonly used for chronic rhinosinusitis (67% of
responses, 95% CI 64–69%). Empirical antimicrobial
therapy was more commonly used for acute conditions
(median 63%, quartile 1 [Q1] 55 to quartile 3 [Q3]
77%) than chronic conditions (median 25%, Q1–Q3
17–44%, P = .01). Culture and susceptibility was used
by at least 20% of respondents in all medical scenarios
including abscesses. There was no diﬀerence between
mixed and companion animal practitioners in the pro-
portion of cases in which C & S was performed (4.7%
higher for companion animal practitioners, 95% CI
2.5 to 12%, P = .199), although recent graduates
(<5 years’ experience) used C & S guided antimicrobial
therapy less commonly than older graduates (6.4%
lower; 95% CI 2.4–11%, P = .002).
Routine prophylactic antimicrobial therapy was used
by 25% (157 of 631) of respondents for routine desex-
ing of cats (95% CI 22–28%) and 25% (154 of 618) of
dogs (95% CI 22–28%). There was no diﬀerence in the
choice of antimicrobial therapy between dogs and cats,
with more than 90% of respondents indicating the use
of aminopenicillins (51%), other b-lactam drugs (25%)
or potentiated aminopenicillins (17%). High importance
rated antimicrobials were used by only 11 respondents
for this indication (3.6%); 6 used 3rd-generation cepha-
losporins (4 in cats, 2 in dogs), 3 reported using ticar-
cillin-clavulanate (1 in cats, 2 in dogs), and 2 reported
using enroﬂoxacin (1 in cats, 1 in dogs). Duration of
therapy did not diﬀer between dogs and cats with a
median duration of therapy of 2 days (Q1–Q3 1–
3 days).
Most respondents used antimicrobials for dental pro-
cedures, with extractions, in both cats (95% [639 of
675], 95% CI 93–96%) and dogs (94% [605 of 643],
95% CI 92–96%), and selection was empiric in 94% of
cat cases (95% CI 92–96%) and 94% of dog cases
(95% CI 92–96%). Antimicrobial therapy was initiated
before dentistry by 64% (665 of 1,041, 95% CI 61–
67%) of practitioners, and the median duration of ther-
apy was 7 days (Q1–Q3 7–10 days). The choice of
antimicrobial diﬀered between dogs and cats with
potentiated aminopenicillins (33%), clindamycin (30%),
and 3rd-generation cephalosporins (21%) used most fre-
quently in cats, and potentiated aminopenicillins (46%)
and clindamycin (35%) used most frequently in dogs.
High importance rating antimicrobials were used by
13% of respondents, with the vast majority being a 3rd-
generation cephalosporin (190 of 203, 94%) which were
predominately administered to cats (168 of 190, 88%).
Overall there were 22,748 antimicrobial therapies
reported across the scenarios. The most commonly used
antimicrobials were aminopenicillins (41% of dog thera-
pies and 41% of cat therapies), followed by ﬂuoro-
quinolones (18% of dog therapies and 11% of cat
therapies), 1st- or 2nd-generation cephalosporins (22%
of dog therapies and 3% of cat therapies), and tetracy-
clines (7% of dog therapies and 17% of cat therapies)
(Table 1). Use of antimicrobials with a high importance
rating ranged from 12 to 47% (median 17%) for cats
and 4 to 42% (median 15%) for dogs among the medi-
cal scenarios. Overall, 3rd-generation cephalosporin use
was more frequent in cats than dogs (16 versus 1.8%,
P < .001) whereas ﬂuoroquinolone use was more fre-
quent in dogs (18 versus 11%, P < .001) (Table 1). In
dogs, ﬂuoroquinolones were also more frequently pre-
scribed for chronic conditions than for acute conditions
(18 and 15% respectively, P < .001). In cats, 3rd-gen-
eration cephalosporins were more frequently prescribed
for chronic than for acute conditions (18 and 14%
respectively, P = .001). The amount of ﬂuoroquinolone
use was similar in dermatological conditions to medical
conditions (11%, 95% CI 10–12%), but more frequent
in otitis externa (41%, 95% CI 39–43%). In otitis
externa, where bacterial rods were seen in cytological
preparations, systemic ﬂuoroquinolone use was reported
by 61% (95% CI 58–64%) of respondents. For medical
conditions in dogs, ﬂuoroquinolones were used most
frequently to treat pneumonia (29%, 95% CI 27–32%),
pyothorax (31%, 95% CI 27–36%), and recurrent
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LUTI disorders (32%, 95% CI 27–37%). In cats, 3rd-
generation cephalosporins were used by more than 25%
of respondents in 4 scenarios; cellulitis/abscesses (26%,
95% CI 24–28%), acute LUTI disease (33%, 95% CI
29–36%), recurrent LUTI disease (25%, 95% CI 21–
31%), and LUTI with concurrent chronic kidney
disease (26%, 95% CI 22–31%). In contrast, 3rd-gen-
eration cephalosporins were much less frequently used
for severe conditions in cats such as pneumonia (7.8%,
95% CI 6.3–9.6%), pyothorax (4.2%, 95% CI 2.8–
6.3%), and peritonitis (3.5%, 95% CI 2.4–5.0%). The
use of 3rd-generation cephalosporins for dermatological
cases was rare (1.9% overall, 95% CI 1.5–2.3%). Use
of other antimicrobials with a high importance rating
was rare and did not diﬀer between dogs and cats (0.6
and 0.5%, respectively). The duration of therapy used
by respondents choosing antimicrobials with a high
importance rating did not diﬀer from those choosing
antimicrobials with low or medium importance rating.
The distribution of the number of prescriptions of
antimicrobials of high importance rating for each par-
ticipant was positively skewed with lowest 50% of
respondents prescribing 12% of these antimicrobials
and higher 50% prescribing the remaining 88%. The
low users of antimicrobials of high importance rating
also used less therapy guided by C & S (38%) than high
users (62%, P < .001). There was no diﬀerence in popu-
lation, IRSAD, year of graduation or percentage time
in companion animal practice, between low and high
users of antimicrobials of high importance rating.
Agreement with AIDAP therapeutic guidelines (post-
hoc) was evaluated for use of empirical therapy, use of
antimicrobial therapy guided by C & S or treatment
without the use of antimicrobials, as well as drug
choice, duration of therapy, and overall agreement.
The data were not normally distributed. Overall agree-
ment was variable, ranging from 0 to 69% between
conditions. There was no diﬀerence between medical
and dermatological conditions in the extent of agree-
ment with the guidelines. The median overall agree-
ment was higher for dogs (38%, Q1–Q3 25–46%) than
for cats (25%, Q1–Q3 16–31%, P < .001). The overall
agreement with the guidelines was less than 33% for 4
conditions; gingivostomatitis (0% agreement for cats,
6.9% agreement for dogs), pyothorax (3.2% agreement
for cats, 0.1% agreement for dogs), peritonitis (0.3%
agreement for cats, 1.0% agreement for dogs), and
acute LUTI disease/cystitis (8.8% agreement for cats,
16% agreement for dogs). For gingivitis and pyotho-
rax, the decision to use empirical antimicrobials or C
& S testing had much higher agreement with AIDAP
guidelines, and the poor overall agreement was due to
poor alignment with the recommendations for drug
selection and duration of therapy recommendations
(Fig 1A,B). For acute cystitis, the poor agreement was
due to the common use of empirical antimicrobial
therapy and failure to culture samples from these
cases, whereas drug selection and duration of therapy
were in better agreement (Fig 1C). Finally, for peri-
tonitis, there was poor agreement in terms of both
empirical choice of drug, use of C & S testing, and
with the selection of drug (Fig 1D), with drugs with a
limited spectrum of activity being chosen for most
cases rather than the extended spectrum (usually via
combination therapy) advocated in the AIDAP guideli-
nes (96%, 95% CI 95–97%). Overall, the choice of
empirical or therapy guided by C & S or treatment
without the use of antimicrobials showed the best
agreement with the guidelines, with a median of 83%
(Q1–Q3 42–95%). There was no diﬀerence between
responses about treatment of dogs or cats. The agree-
ment with the guidelines with respect to choice of
drug, where indicated, did not diﬀer between dogs and
cats, with an overall median 43% (Q1–Q3 5–57%).
Similarly, agreement with the guidelines on duration of
therapy and drug selection, where indicated, had the
same level of agreement between dogs and cats (overall
median 36%, Q1–Q3 25–67%). There was no signiﬁ-
cant diﬀerence in agreement with AIDAP guidelines
for practitioners who were recent graduates (past
5 years) compared to older graduates, nor between
practitioners who were predominately small animal
veterinarians compared to veterinarians working in
“mixed practices.”
Discussion
This study has shown that empirical antimicrobial
therapy is very common in Australian veterinary
practice as is indicated for many conditions both in vet-
erinary12 and medical practice.13 This is a similar
Table 1. Overall frequency of antibiotic use across










327 (3.4) 2,908 (22)
3rd-generation
cephalosporins
1,548 (16) 240 (1.8)
Aminoglycosides Gentamicin 20 (0.2) 54 (0.4)
Amikacin 3 (<0.1) 7 (<0.1)
Total 23 (0.2) 61 (0.5)
b-Lactams Unpotentiated 487 (5.1) 492 (3.7)




46 (0.5) 69 (0.5)
Total 3,863 (41) 5,462 (41)
Macrolides 706 (7.4) 617 (4.7)
Chloramphenicol 0 (0) 2 (<0.1)
Tetracyclines 1,579 (17) 953 (7.2)
Fluoroquinolones 1,065 (11) 2,389 (18)
Metronidazole 327 (3.4) 374 (2.8)
Rifampicin 0 (0) 29 (0.2)
Trimethoprim/
sulfonamides
47 (0.5) 161 (1.2)
Other 27 (0.3) 40 (0.3)
Total 9,512 13,236
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outcome to that reported in a cross-sectional study of
practicing veterinarians in New Zealand where therapy,
guided by C & S, was used in 19% of cases.14 Fluoro-
quinolones were used empirically at a high rate for
speciﬁc conditions in dogs, as were 3rd-generation
cephalosporins in cats. The rate of empiric 3rd-genera-
tion cephalosporin use in cats in this study is similar to
ﬁndings by others.15,16 Prophylactic antimicrobial use
for routine desexing was less common. The most com-
monly used antimicrobial classes are aminopenicillins,
particularly potentiated aminopenicillins, ﬂuoro-
quinolones, early-generation cephalosporins, and tetra-
cyclines. This is consistent with ﬁndings in New
Zealand (amoxicillin-clavulanate 48%, cephalexin
31%),14 Canada (aminopenicillins 56%, cephalexin
33%),16 and the United Kingdom (aminopenicillins
59%, cephalexin 13%).15 Interestingly, there was very
low use of older broad-spectrum antimicrobials such as
trimethoprim sulfonamide combinations (0.9%) and
chloramphenicol (0.01%). There was also limited use of
other drugs with a low importance rating, such as
macrolides (6%), which have traditionally been main-
stays of therapy, particularly in cats.
Empirical antimicrobial therapy was less common in
this survey than in the only other survey of antimicro-
bial usage in dogs and cats in Australia, which was per-
formed in 1997. In that study, empirical use for acute
conditions ranged from 76 to 94% of cases,8 whereas in
this study, the range was 19–79%. The increased use of
C & S testing as a tool for directing antimicrobial ther-
apy that was detected in this survey is likely to reﬂect
improved antimicrobial stewardship and might be
expected to improve clinical outcomes in veterinary
practices, although there are likely to be concerns about
its cost-eﬀectiveness for many animal owners. In addi-
tion, this survey did not investigate the methods used
for C & S testing by veterinarians or veterinary labora-
tories. Use of rigorous methodology and veterinary
speciﬁc break points is critical for ensuring reliable
results from C & S testing. Regardless, this promising
trend may reﬂect a growing willingness of the public to
invest in disease investigations, an increase in these ser-
vices being oﬀered to clients, increased awareness by
the profession of the beneﬁt of testing, and/or an
increase in treatment failures necessitating further inves-
tigation. Interestingly, C & S testing was used relatively
frequently in the treatment of abscess (21%). Further
investigation is warranted to evaluate the reasoning
behind the high level of C & S testing for this scenario.
The results may indicate a degree of prevarication bias
in the survey (ie, survey respondents altering their
answers to survey questions in a way that matches the
perceived expectations of those carrying out the survey)
and should be validated.
The AIDAP therapeutic guidelines recommend the
use of cefovecin, the only 3rd-generation cephalosporin
registered for use in companion animals in Australia,
only for cases where there is likely to be poor compli-
ance with oral antimicrobial therapy. As a reﬂection of
this, 3rd-generation cephalosporins were much more
commonly used in cats compared to dogs by practition-
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Fig 1. Agreement with Australasian Infectious Disease Advisory Panel guidelines for choice of empirical or antimicrobial therapy guided
by culture and susceptibility (C & S), choice of drug and duration of therapy, and overall agreement with the guidelines for treatment of
(A) gingivitis, (B) pyothorax, (C) acute cystitis, and (D) peritonitis. White columns indicate treatment choices for cats, and black columns
indicate the treatment choices for dogs.
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were those in which infection could be eﬀectively trea-
ted with orally administered antimicrobial agents with a
lower importance rating (ie, cellulitis/bite-wound abscess
and LUTI). Further, survey ﬁndings highlight the need
for LUTI in cats to be conﬁrmed by in-house micro-
scopic evaluation of a urine sample before initiating
antimicrobial therapy due to the high prevalence of
noninfectious cystitis in cats.17–19 The reported high
usage of 3rd-generation cephalosporins in cats likely
reﬂects poor compliance in administration of oral drugs
to cats compared to dogs, as cats are less likely to
ingest medications in food, as has been found in a
recent study from the United Kingdom.20
Diﬀerent factors may account for ﬂuoroquinolone
administration to dogs. The rate of ﬂuoroquinolone
administration for some of the scenarios included in this
survey was higher than expected. In complicated canine
otitis cases involving Gram-negative pathogens, such as
Pseudomonas aeruginosa with rupture of the tympanic
membrane, there are limited therapeutic options and
the use of topical ﬂuoroquinolones in this scenario is
often warranted. However, the high frequency of sys-
temic use of ﬂuoroquinolones for both complicated and
uncomplicated otitis cases suggests a need for improved
antimicrobial stewardship by veterinarians in treating
this disease. Awareness by veterinarians of the high
concentrations of ﬂuoroquinolones that can be achieved
with topically applied formulations, and hence low risk
of resistance development,21 may be lacking. Eﬀorts
should be made to alert veterinary practitioners that
combined topical and systemic antimicrobial therapy
should only be necessary in complicated cases where
there is middle ear involvement with vestibular or facial
nerve dysfunction and especially when there is
osteomyelitis of the tympanic bulla. The use of systemic
therapy alone is less likely to achieve the concentrations
at the site of infection required to eliminate the patho-
gen and prevent development of resistance.22 The intro-
duction of the AIDAP therapeutic guidelines, after this
survey, may have improved veterinary prescribing in
this area and ongoing monitoring of prescribing prac-
tices is warranted.
The Australian Veterinary Association has also
recently recommended that antimicrobials with a high
importance rating such as 3rd-generation cephalospor-
ins and ﬂuoroquinolones “should be used only when
other options are unavailable and wherever possible
only after susceptibility testing has been completed”.23
Several drugs with a high importance require autho-
rization before administration in human medicine in
Australia.9 Half of the population of veterinarians
that participated in this survey accounted for 88% of
the usage of antimicrobials of high importance rating.
The factors that inﬂuence these prescribing habits
could not be elucidated in this study. There was no
diﬀerence in population or socioeconomic variables
based on postcode, or in year of graduation of
prescribers. The concurrent low use of directed antimi-
crobial therapy in low users of antimicrobials of
high importance rating may suggest that these practi-
tioners have a client base that is less willing to invest
economically in their animals, as both C & S testing
and antimicrobials of high importance rating tend to
be expensive in Australian veterinary practices.
However, it may also reﬂect a more proactive clientele
that present cases earlier and therefore the need for
antimicrobials of high importance rating, and directed
therapy, is perceived to be less. Further investigation
into the factors driving the high use of these antimi-
crobials by a selection of the veterinary population is
warranted.
There have been no previous reports on the fre-
quency of antimicrobial use for routine surgical proce-
dures in companion animal practice in Australia.
Antibiotics are considered unnecessary for routine short
surgeries conducted under sterile conditions, such as
routine desexing.12 Over 75% of respondents in this
survey did not use antimicrobial prophylaxis for rou-
tine desexing. However, with almost one quarter of
Australian veterinarians still routinely using antimicro-
bials for neutering, and the number of these procedures
performed in general practice, this topic requires a
speciﬁc education program. Antimicrobials were fre-
quently used in patients undergoing dental procedures
including extractions in this survey (90% of respon-
dents). The AIDAP guidelines recommend prophylactic
antimicrobials if there are extractions or likely to be
bleeding.12 Interestingly, as the release of the AIDAP
guidelines, the recommendations for use of antimicro-
bials in dentistry have changed in human medicine with
antimicrobials now only recommended for dental pro-
cedures performed on patients at a high risk for cardiac
disease, to mitigate against the risk of infective endo-
carditis.24 In addition, these recommendations are now
not in line with current accepted veterinary practice,
which does not recommend the use of prophylactic
antimicrobial therapy for routine dental procedures.25
This suggests that further study of the need for antimi-
crobial therapy after dental procedures is warranted in
veterinary medicine.
Agreement with AIDAP guidelines was used as an
indicator of gold standard therapy in this survey. The
guidelines were introduced in 2013, 2 years after the
survey was conducted, so some changes in usual ther-
apy may have occurred after the survey was conducted
while guidelines were being generated. However, there
were no signiﬁcant introductions of new antimicrobial
drugs into the Australian companion animal market
over this period and use of an indicator of best practice
will allow for further investigation of factors confound-
ing prescribing habits. Disagreement with guidelines
was mainly due to drug selection and duration of ther-
apy. This was due to both overuse of therapy and lack
of recognition and treatment of severe sepsis. There was
no diﬀerence in the prescribing habits between
recently graduated veterinarians compared to older
veterinarians.
There are several features of this study that may have
inﬂuenced the results. Nonrandom, self-selection of sur-
vey respondents can result in selection bias; for exam-
ple, veterinarians more aware or interested in
antimicrobial stewardship may have been more likely to
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respond. Recall bias can occur with retrospective ques-
tionnaire-based surveys. In order to minimize this, gen-
eric hypothetical scenarios were posed rather than
asking clinicians to recall speciﬁc cases. Prevarication
bias was also possible. Given that this was not an
anonymous survey, respondents may have felt pressured
to respond in a certain way resulting in under- or over-
reporting of prescribing practices and use of C & S test-
ing. While bias may have aﬀected responses to some
questions, it is the authors’ opinion, given the consis-
tency with other studies and our clinical experience, we
can have a reasonable level of conﬁdence in the external
validity of these ﬁndings.
In conclusion, this survey has shown that generally
the choice to use antimicrobials by Australian veteri-
narians is appropriate and that in the majority of
scenarios, antimicrobials with a low or medium impor-
tance rating are used. The use of antimicrobials with a
high importance rating, particularly ﬂuoroquinolones
in dogs and 3rd-generation cephalosporins in cats, as
an empirical therapeutic choice warrants further inves-
tigation now that the AIDAP guidelines have been
introduced.
Footnote
a StataCorp, 2013, Stata Statistical Software: Release 13, Stata-
Corp LP, College Station, TX
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